MedTrace Logo

An Exploratory Study of MT-2990 in Patients With AAV

NCT06196905 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-02-04

No results posted yet for this study

Summary

To explore the efficacy, safety, pharmacokinetics and mechanism of action of MT-2990 in patients with AAV.

Conditions

  • Antineutrophil Cytoplasmic Antibody (ANCA) -Associated Vasculitis (AAV)

Interventions

DRUG

MT-2990

i.v. infusion

Sponsors & Collaborators

  • Tanabe Pharma Corporation

    lead INDUSTRY

Principal Investigators

  • General Manager · Tanabe Pharma Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-24
Primary Completion
2026-01-14
Completion
2026-01-14
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06196905 on ClinicalTrials.gov